Sign up to The Irish Times Archive (1859 - 2008)My Account »
Thu 10 Oct 2009Tests show Tysabri helps Crohn's patients, says Elan
PATIENTS WITH Crohn’s disease are less likely to be hospitalised if they are using Tysabri, according to figures produced by the drug’s developers, Irish biotech group Elan and US-based Biogen Idec.
Results released yesterday of a new analysis of three late-stage clinical trials showed Tysabri benefited patients with moderate to severe Crohn’s – an inflammatory disease of the intestine and bowel.
Choose a Subscription type - required
